IN8bio Presents Phase 1 INB-100 Trial Data At EHA 2024; 100% Of Evaluable Leukemia Patients Remain Alive, Progression-Free, And In Durable CR Through One Year; Demonstrates In Vivo Expansion And Persistence Of Haplo-Matched Allogeneic Gamma-Delta T Cell Therapy
Portfolio Pulse from Benzinga Newsdesk
IN8bio presented Phase 1 INB-100 trial data at EHA 2024, showing 100% of evaluable leukemia patients remain alive, progression-free, and in durable complete remission through one year. The trial demonstrated in vivo expansion and persistence of haplo-matched allogeneic gamma-delta T cell therapy.
June 13, 2024 | 8:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IN8bio's Phase 1 INB-100 trial data shows 100% of evaluable leukemia patients in durable complete remission at one year, demonstrating the potential of their allogeneic gamma-delta T cell therapy.
The trial results are highly positive, showing 100% of patients in durable remission, which is a significant achievement for IN8bio's therapy. This could lead to increased investor confidence and a potential rise in stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100